Literature DB >> 17914175

Optimizing expression of Streptococcus pneumoniae surface protein a, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3.

Marcelo Silva1, Joaquin Cabrera-Crespo, Maria E Sbrogio-Almeida, Eliane N Miyaji, Paulo L Ho, Luciana C C Leite, Alexandre P Y Lopes.   

Abstract

Streptococcus pneumoniae is the agent responsible for infections such as pneumonia, otitis media, and meningitis. Among virulence factors, the Pneumococcal surface protein A (PspA) has been shown to be immunogenic and protective in mice, and is thus a good vaccine candidate. PspA has been classified into 6 clades and 3 families. Initially, pspA fragments, clades 1 and 3, were cloned into the pAE-6His expression vector. Proteins were expressed in Escherichia coli BL21(DE3) and purified by affinity and anion exchange chromatographies, with a yield of 11 mg/l of culture. Due to plasmid instability in E. coli, another construct using pspA1 was obtained based on pET-37b(+), which was shown to be stable in E. coli and increased the yield approximately 3-fold. Our results show good conditions for scale-up. Sera from immunized mice recognized PspA in total extracts of S. pneumoniae strains: anti-rPspA1p sera recognized native PspA clades 1 (+++), 2 (++) and 4 (+) and anti-rPspA3p sera recognized PspA clades 1 (+), 2 (+), 3 (+++) and 4 (+). The cross-reactivity pattern obtained confirms the notion that proteins from both families should be included for development of a broad-coverage vaccine; lower-cross reactivity between rPspAs of family 2 indicates that it may be necessary to include 2 proteins from this family.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914175     DOI: 10.1007/s12033-007-0043-z

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  20 in total

1.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  proBA complementation of an auxotrophic E. coli strain improves plasmid stability and expression yield during fermenter production of a recombinant antibody fragment.

Authors:  M Fiedler; A Skerra
Journal:  Gene       Date:  2001-08-22       Impact factor: 3.688

3.  Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.

Authors:  S K Hollingshead; R Becker; D E Briles
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil.

Authors:  Fabiana Cristina Pimenta; Fátima Ribeiro-Dias; Maria Cristina C Brandileone; Eliane N Miyaji; Luciana C C Leite; Ana Lúcia S Sgambatti de Andrade
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Production and characterization of the functional fragment of pneumococcal surface protein A.

Authors:  M J Jedrzejas; S K Hollingshead; J Lebowitz; L Chantalat; D E Briles; E Lamani
Journal:  Arch Biochem Biophys       Date:  2000-01-01       Impact factor: 4.013

6.  Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.

Authors:  M J Crain; W D Waltman; J S Turner; J Yother; D F Talkington; L S McDaniel; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

7.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

Authors:  G S Nabors; P A Braun; D J Herrmann; M L Heise; D J Pyle; S Gravenstein; M Schilling; L M Ferguson; S K Hollingshead; D E Briles; R S Becker
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

8.  A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide.

Authors:  C R R Ramos; P A E Abreu; A L T O Nascimento; P L Ho
Journal:  Braz J Med Biol Res       Date:  2004-07-20       Impact factor: 2.590

9.  Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae.

Authors:  W D Waltman; L S McDaniel; B M Gray; D E Briles
Journal:  Microb Pathog       Date:  1990-01       Impact factor: 3.738

Review 10.  Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Authors:  E AlonsoDeVelasco; A F Verheul; J Verhoef; H Snippe
Journal:  Microbiol Rev       Date:  1995-12
View more
  3 in total

1.  Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.

Authors:  Fabrice Godfroid; Philippe Hermand; Vincent Verlant; Philippe Denoël; Jan T Poolman
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

2.  Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response.

Authors:  Catia T Perciani; Giovana C Barazzone; Cibelly Goulart; Eneas Carvalho; Joaquin Cabrera-Crespo; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki
Journal:  Clin Vaccine Immunol       Date:  2013-04-03

3.  Cloning approach and functional analysis of anti-intimin single-chain variable fragment (scFv).

Authors:  Márcio A Menezes; Karina A Aires; Christiane Y Ozaki; Renato M Ruiz; Milton Ca Pereira; Patrícia Ae Abreu; Waldir P Elias; Oscar Hp Ramos; Roxane Mf Piazza
Journal:  BMC Res Notes       Date:  2011-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.